# Advanced Cell Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advanced-cell-diagnostics

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.acdbio.com
- Total disclosed funding: $35M
- Latest round: Series C (Jun 18, 2015)
- Investors on record: 5

## About

Advanced Cell Diagnostics, Inc. specializes in molecular diagnostics, offering innovative assays that facilitate the detection and visualization of RNA and protein targets in biological samples.Advanced Cell Diagnostics, Inc. focuses on advanced molecular diagnostics offering innovative solutions for gene expression analysis. The company is headquartered in Hayward, US. Founded by Calvin Carter and Yuling Luo, ACDBio has successfully raised USD 22.00 mn in Series C financing on June 18, 2015, led by Summit Partners and supported by investors including Kenson Ventures, New Leaf Venture Partners, and 5Y Capital. The company has completed 4 funding deals to date, achieving a current valuation of USD 117.863 mn.ACDBio specializes in advanced molecular diagnostics through its core offerings, which include the RNAscope™, BaseScope™, and miRNAscope™ assays. These products utilize in situ hybridization (ISH) technology to enable the detection and visualization of RNA and protein targets in tissue samples. The assays address critical challenges across biopharma, neuroscience, and oncology, serving a diverse clientele that includes academic and research institutions, biotechnology firms, and pharmaceutical companies globally, with a strong presence in North America, Europe, and Asia.ACDBio generates revenue primarily from direct sales of its flagship products, including RNAscope™ assays and related reagents, to research institutions and biopharmaceutical companies. The company structures transactions as direct sales, allowing clients to procure products according to their specific research needs. Additionally, ACDBio partners with distributors to enhance accessibility in various markets, tailoring pricing strategies to fit the needs of research organizations through options such as bulk purchasing or subscription models for ongoing access to vital reagents and support services.Following the recent Series C financing of USD 22.00 mn in June 2015, Advanced Cell Diagnostics, Inc. aims to innovate and expand its product offerings, focusing on upcoming assays designed to enhance research capabilities in molecular diagnostics. The company plans to enter new geographic markets, targeting regions such as Asia and Europe by 2026, which will broaden its customer base and increase market presence. The funds raised will be utilized to support the development of these new products and facilitate market entry strategies.

## Funding rounds

- Series C, Jun 18, 2015, $22M — Summit Partners, New Leaf Venture Partners, 5Y Capital, Kenson Ventures
- Series B, Nov 1, 2012, $8M — New Leaf Venture Partners, 5Y Capital, Morningside
- Series A, Sep 2, 2009, $5.4M — 5Y Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B
- Summit Partners (https://capitalatlas.ai/funds/summit-partners) — Series C
- Kenson Ventures (https://capitalatlas.ai/funds/kenson-ventures) — Series C